AG2R LA Mondiale Gestion D Actifs acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 46,328 shares of the biopharmaceutical company's stock, valued at approximately $5,100,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of GILD. Price T Rowe Associates Inc. MD increased its holdings in Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares during the last quarter. Nuveen LLC bought a new stake in shares of Gilead Sciences in the 1st quarter valued at approximately $620,415,000. GAMMA Investing LLC increased its holdings in shares of Gilead Sciences by 13,891.1% in the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock valued at $285,761,000 after acquiring an additional 2,532,070 shares during the last quarter. Los Angeles Capital Management LLC increased its holdings in shares of Gilead Sciences by 422.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company's stock valued at $282,706,000 after acquiring an additional 2,040,261 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in shares of Gilead Sciences by 30.1% in the 4th quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company's stock valued at $801,655,000 after acquiring an additional 2,005,863 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Gilead Sciences
In other news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $296,325.00. Following the completion of the sale, the chief financial officer owned 160,110 shares of the company's stock, valued at approximately $18,977,838.30. This trade represents a 1.54% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 82,000 shares of company stock worth $9,371,330. Corporate insiders own 0.27% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on GILD shares. Dbs Bank upgraded Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Royal Bank Of Canada boosted their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a report on Friday, August 8th. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a report on Friday, July 25th. Finally, Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a report on Tuesday, August 19th. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $115.39.
Get Our Latest Stock Report on Gilead Sciences
Gilead Sciences Trading Up 2.3%
Shares of GILD stock opened at $117.86 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 1 year low of $81.57 and a 1 year high of $121.83. The stock has a fifty day moving average of $113.97 and a two-hundred day moving average of $110.07. The firm has a market capitalization of $146.24 billion, a PE ratio of 23.48, a price-to-earnings-growth ratio of 0.78 and a beta of 0.36.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the firm posted $2.01 EPS. The firm's quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences's dividend payout ratio is 62.95%.
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
